PubRank

Robert M Sharkey

Author PubWeight™ 66.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm 2010 3.23
2 Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006 2.79
3 Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2005 2.55
4 A novel method of 18F radiolabeling for PET. J Nucl Med 2009 2.35
5 Renal dosimetry: ready for biological effective dose? Cancer Biother Radiopharm 2010 2.24
6 Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem 2010 1.76
7 Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 2006 1.50
8 Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging 2013 1.49
9 A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med 2010 1.47
10 New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2005 1.45
11 Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2007 1.35
12 Pretargeted molecular imaging and radioimmunotherapy. Theranostics 2012 1.31
13 Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med 2006 1.18
14 High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem 2011 1.17
15 Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther 2002 1.15
16 A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 2008 1.15
17 Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther 2010 1.13
18 Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005 1.09
19 Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011 1.05
20 Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. J Nucl Med 2011 1.00
21 New lyophilized kit for rapid radiofluorination of peptides. Bioconjug Chem 2012 1.00
22 Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003 0.99
23 The radiolabeling of proteins by the [18F]AlF method. Appl Radiat Isot 2011 0.98
24 Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther 2013 0.96
25 Radiofluorination using aluminum-fluoride (Al18F). EJNMMI Res 2013 0.96
26 Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med 2009 0.95
27 Optimized labeling of NOTA-conjugated octreotide with F-18. Tumour Biol 2011 0.95
28 Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med 2010 0.94
29 Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res 2008 0.93
30 Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med 2004 0.93
31 Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 2003 0.93
32 Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res 2011 0.92
33 Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 2003 0.91
34 Cancer Imaging and Therapy with Bispecific Antibody Pretargeting. Update Cancer Ther 2007 0.90
35 Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Clin Cancer Res 2004 0.90
36 Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin Cancer Res 2006 0.89
37 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 2003 0.89
38 Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 2003 0.88
39 Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2002 0.88
40 Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res 2005 0.87
41 RADAR commentary: Evolution and current status of dosimetry in nuclear medicine. J Nucl Med 2011 0.86
42 Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med 2012 0.85
43 Al(18) F labeling of peptides and proteins. J Labelled Comp Radiopharm 2014 0.83
44 Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. Eur J Nucl Med Mol Imaging 2014 0.83
45 Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody. Cancer 2010 0.82
46 Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer. J Nucl Med 2012 0.80
47 Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap. Cancer Biother Radiopharm 2009 0.79
48 Using antibodies to target cancer therapeutics. Expert Opin Biol Ther 2012 0.79
49 Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga. J Nucl Med 2011 0.78
50 Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Res 2012 0.78
51 Radioimmunotherapy of non-Hodgkin's lymphoma revisited. J Nucl Med 2005 0.78
52 A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies. Clin Cancer Res 2007 0.77
53 Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy. J Nucl Med 2005 0.77
54 Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide. Cancer Biother Radiopharm 2014 0.77
55 Recent progress in cancer therapy with radiolabeled monoclonal antibodies. Ther Deliv 2011 0.76
56 Al18F: a new standard for radiofluorination. J Nucl Med 2013 0.76
57 Blood-based red marrow dosimetry: where's the beef? J Nucl Med 2005 0.75
58 Radioactive antibodies: a historical review of selective targeting and treatment of cancer. Hosp Pract (1995) 2010 0.75
59 Renal dosimetry: ready for biological equivalent dose? Response to medical internal radiation dose and European association of nuclear medicine committee letters. Cancer Biother Radiopharm 2010 0.75
60 Renal dosimetry: ready for BED? Response to the Italian researchers. Cancer Biother Radiopharm 2011 0.75
61 Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. Clin Lymphoma 2003 0.75
62 Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts. Mol Imaging Biol 2015 0.75